Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

NCT05044039 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Non-hodgkin Lymphoma
Acute Lymphocytic Leukemia

Interventions

DRUG: Duvelisib

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]